These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 11551261)

  • 1. Tolerability of rofecoxib.
    Asero R
    Allergy; 2001 Sep; 56(9):916-7. PubMed ID: 11551261
    [No Abstract]   [Full Text] [Related]  

  • 2. Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib.
    Sánchez-Borges M; Caballero-Fonseca F; Capriles-Hulett A
    Ann Allergy Asthma Immunol; 2005 Jan; 94(1):34-8. PubMed ID: 15702813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term and long-term tolerability of rofecoxib in patients with prior reactions to nonsteroidal anti-inflammatory drugs.
    Nettis E; Colanardi MC; Ferrannini A; Tursi A
    Ann Allergy Asthma Immunol; 2005 Jan; 94(1):29-33. PubMed ID: 15702812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urticaria and angioedema from cyclooxygenase-2 inhibitors.
    Kelkar PS; Butterfield JH; Teaford HG
    J Rheumatol; 2001 Nov; 28(11):2553-4. PubMed ID: 11708434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerability of rofecoxib versus naproxen.
    Rusche JM
    Ann Intern Med; 2004 Jun; 140(12):1059; author reply 1060. PubMed ID: 15197028
    [No Abstract]   [Full Text] [Related]  

  • 6. Tolerability of rofecoxib versus naproxen.
    Jenkinson ML
    Ann Intern Med; 2004 Jun; 140(12):1059-60; author reply 1060. PubMed ID: 15197027
    [No Abstract]   [Full Text] [Related]  

  • 7. Tolerability of rofecoxib versus naproxen.
    Hanauer LB
    Ann Intern Med; 2004 Jun; 140(12):1059; author reply 1060. PubMed ID: 15197026
    [No Abstract]   [Full Text] [Related]  

  • 8. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients.
    Senna G; Bilò MB; Antonicelli L; Schiappoli M; Crivellaro MA; Bonadonna P; Dama AR
    Eur Ann Allergy Clin Immunol; 2004 Jun; 36(6):215-8. PubMed ID: 15329003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Gynecomastia secondary to rofecoxib].
    Martínez JA; Tejada González P; Gutiérrez Sanpedro N; González Blanco P
    Med Clin (Barc); 2002 Jun; 118(20):798-9. PubMed ID: 12049701
    [No Abstract]   [Full Text] [Related]  

  • 10. Lessons from the withdrawal of rofecoxib.
    Dieppe PA; Ebrahim S; Martin RM; Jüni P
    BMJ; 2004 Oct; 329(7471):867-8. PubMed ID: 15485938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolerability of cyclooxygenase 2 inhibitors and the advisability of oral challenge.
    Rodríguez M; Enrique E; Castello JV; de Mateo JA; Roca B; Malek T
    Ann Allergy Asthma Immunol; 2003 Dec; 91(6):589. PubMed ID: 14700447
    [No Abstract]   [Full Text] [Related]  

  • 12. Probable rofecoxib-induced thrombocytopenia.
    Kentos A; Robin V; Lambermont M; Jurdan M; Pignarelli M; Feremans W
    Rheumatology (Oxford); 2003 May; 42(5):699-700. PubMed ID: 12709555
    [No Abstract]   [Full Text] [Related]  

  • 13. [Rofecoxib and gynecomastia: the first case].
    Schmutz JL; Barbaud A; Trechot P
    Ann Dermatol Venereol; 2004; 131(8-9):856. PubMed ID: 15505566
    [No Abstract]   [Full Text] [Related]  

  • 14. Celecoxib and rofecoxib.
    Brinker AD; Bonnel RA; Feight AG; Nourjah P
    J Am Dent Assoc; 2001 Nov; 132(11):1502, 1504. PubMed ID: 11806062
    [No Abstract]   [Full Text] [Related]  

  • 15. Rofecoxib-induced pseudoporphyria.
    Markus R; Reddick ME; Rubenstein MC
    J Am Acad Dermatol; 2004 Apr; 50(4):647-8. PubMed ID: 15034522
    [No Abstract]   [Full Text] [Related]  

  • 16. Rofecoxib and the risk of adverse upper gastrointestinal effects.
    Whitney E
    JAMA; 2000 Apr; 283(15):1960; author reply 1961. PubMed ID: 10789660
    [No Abstract]   [Full Text] [Related]  

  • 17. Celecoxib- and rofecoxib-induced delirium.
    Macknight C; Rojas-Fernandez CH
    J Neuropsychiatry Clin Neurosci; 2001; 13(2):305-6. PubMed ID: 11449042
    [No Abstract]   [Full Text] [Related]  

  • 18. Severe cholestasis and acute renal failure related to rofecoxib.
    Linares P; Vivas S; Jorquera F; Olcoz JL; de Leon B; Oritz de Urbina J
    Am J Gastroenterol; 2004 Aug; 99(8):1622-3. PubMed ID: 15307886
    [No Abstract]   [Full Text] [Related]  

  • 19. Simultaneous presentation of rofecoxib-induced acute hepatitis and acute interstitial nephritis.
    Haider M; Gain E; Khadem G; Pilmore H; Yun K; Jayasinghe N; Walker R
    Intern Med J; 2005 Jun; 35(6):370-2. PubMed ID: 15892770
    [No Abstract]   [Full Text] [Related]  

  • 20. Rofecoxib and the risk of adverse upper gastrointestinal effects.
    Freston J
    JAMA; 2000 Apr; 283(15):1960; author reply 1961. PubMed ID: 10789659
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.